ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.23
0.00%
US Tech 100
19,540.40
-0.20%
S&P 500
5,745.37
0.40%
US Dollar vs CAD
1.34769
0.00%
Bitcoin
65,586.99
0.62%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) News

AGEN

Agenus (AGEN)

Agenus Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AGEN
DateTimeSourceHeadlineSymbolCompany
09/26/20244:45AMPR Newswire (US)AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:AGENAgenus Inc
09/23/20244:45AMPR Newswire (US)AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:AGENAgenus Inc
09/19/20244:45AMPR Newswire (US)Contact The Gross Law Firm by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN)NASDAQ:AGENAgenus Inc
09/16/20244:45AMPR Newswire (US)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) ShareholdersNASDAQ:AGENAgenus Inc
09/13/20249:00AMBusiness WireBotensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024NASDAQ:AGENAgenus Inc
09/11/20241:25PMPR Newswire (US)AGEN INVESTOR ALERT: Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class ActionNASDAQ:AGENAgenus Inc
09/09/20246:30AMBusiness WireBotensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024NASDAQ:AGENAgenus Inc
09/03/20246:30AMBusiness WireAgenus to Participate in September Investor ConferencesNASDAQ:AGENAgenus Inc
08/08/20243:49PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
08/08/20243:47PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AGENAgenus Inc
08/08/20243:45PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
08/08/20243:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
08/08/20243:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
08/08/20246:00AMBusiness WireAgenus Announces Appointment of Tom Harrison to Board of DirectorsNASDAQ:AGENAgenus Inc
08/08/20246:00AMBusiness WireAgenus Reports Second Quarter 2024 Operational and Financial ResultsNASDAQ:AGENAgenus Inc
08/07/20249:58AMBusiness WireAgenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant CancersNASDAQ:AGENAgenus Inc
08/02/20243:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
07/26/20246:00AMBusiness WireAgenus to Provide Second Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
07/18/20246:00AMBusiness WireAgenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerNASDAQ:AGENAgenus Inc
06/28/202410:10AMBusiness WireSignificant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI ConferenceNASDAQ:AGENAgenus Inc
06/27/20246:30AMBusiness WireCancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical StudiesNASDAQ:AGENAgenus Inc
06/18/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
06/18/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
06/18/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
06/18/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
06/17/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
06/17/20246:00AMBusiness WireAgenus Announces Appointment of Dr. Jennifer Buell to Its Board of DirectorsNASDAQ:AGENAgenus Inc
06/14/20243:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
06/13/20244:15AMBusiness WireNature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50NASDAQ:AGENAgenus Inc
06/04/20246:30AMBusiness WireAgenus Announces Virtual Annual Shareholders MeetingNASDAQ:AGENAgenus Inc
 Showing the most relevant articles for your search:NASDAQ:AGEN

Your Recent History

USOTC
IBGR
Nexus Energy Services (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
TGRP
TRON (PK)
USOTC
NBRI
North Bay Resources (PK)
USOTC
IDVV
International Endeavors (PK)
USOTC
TPTW
TPT Global Tech (CE)
USOTC
VHAI
Vocodia (PK)
USOTC
ENZC
Enzolytics (PK)
NASDAQ
RNAZ
TransCode Therapeutics
USOTC
VPLM
Voip Pal Com (QB)
USOTC
AHRO
Authentic (PK)
USOTC
AXXA
Exxe (PK)
USOTC
HIRU
Hiru (PK)
NASDAQ
NVDA
NVIDIA
USOTC
TSOI
Therapeutic Solutions (PK)
USOTC
FNMA
Fannie Mae (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved